Prophylaxis and Management of Graft-Versus-Host Disease After Stem-Cell Transplantation for Haematological Malignancies: Updated Consensus Recommendations of the European Society for Blood and Marrow Transplantation
Source : https://pubmed.ncbi.nlm.nih.gov/38184001/
Graft-versus-host disease (GVHD) is a major factor contributing to mortality and morbidity after allogeneic haematopoietic stem-cell transplantation (HSCT). In the last 3 years, there has been regulatory approval of new...
In a recent update to clinical practice guidelines, belumosudil was added to available treatment options for steroid-refractory chronic GVHD.
Crowdsourcing Skin Demarcations of Chronic Graft-Versus-Host Disease in Patient Photographs: Training Versus Performance Study
Source : https://pubmed.ncbi.nlm.nih.gov/38147369/
Crowds of nonexpert raters can demarcate cGVHD images with good overall performance. Tracking the top 5 most reliable raters provided optimal results, obtaining the best performance with the lowest number...
The nonexpert crowds achieved good overall performance for segmenting cGVHD-affected skin with minimal training, achieving a median surface area error of <12% of skin pixels for all crowds in high-/low-feedback groups.
Novel Pharmacological Treatment Options of Steroid-Refractory Graft-Versus-Host Disease
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10718798/
Graft-versus-host disease (GVHD) is a potentially fatal complication of allogeneic hematopoietic stem cell transplant. The mainstay of treatment is corticosteroids, which are ineffective in 30-50% of cases. Steroid-refractory GVHD (SR-GVHD)...
For chronic GVHD, approved options include ruxolitinib with an ORR of ≤62%, ibrutinib with an ORR of ≤77%, and belumosudil with an ORR of ≤77%.
Diagnostic and Prognostic Role of Elafin in Skin Acute Graft Versus Host Disease: a Systematic Review
Source : https://pubmed.ncbi.nlm.nih.gov/38112182/
Elafin is a significant biomarker for diagnosis and prognosis of skin aGVHD and should be assessed within 2 weeks of the onset of the disease.
Elafin can potentially be the specific biomarker associated with the diagnosis and prognosis of skin acute GVHD and it should be investigated within 14 days of onset of acute GVHD.
Separation of GVL From GVHD - Location, Location, Location
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10728488/
Allogeneic hematopoietic cell transplantation (HCT) is a curative therapy for various hematologic malignancies.
Specific inhibition of donor T-cell migration to GVHD target tissues while preserving migration to the bone marrow may represent a novel strategy to separate GVL from GVHD.